PPP Quiz III Flashcards
Describe the pain pathway
Action potential travels along the 1st neuron, meets the synapse, and transacted to the second order neuron, and then to the brain.
Where does the Spinothalamic tract go to?
PAIN to the higher centers
MOA of NSAIDS
Inhibit COX to decrease synthesis of prostaglandins
Describe the physiology of Eicosanoids
PG sensitive AFFERENT nerves to pain; Increase of prostaglandins lead to increase sensitivity to pain fibers by altering the phosphorylation status of the neuron
Where do NSAIDS block?
COX; Conversion of Arachidonic acid to prostaglandins
What does Ibuprofen block?
COX1 & COX2
What does aspirin block (81mg)?
COX1
Name the housekeeping functions of PG: Stomach
COX1 to PGE2: Decrease of gastric acid secretion; Increase of mucus and bicarbonate secretion
Name the housekeeping functions of PG: Renal
COX2 to PGE2, PGI2: Increase renal blood flow; Increase glomerular filtration rate
Name the housekeeping functions of PG: Platelet
COX1 to TXA2; Increase of platelet aggregation
Name the housekeeping functions of PG: Endothelial Cells
COX2 to PGI2: Decrease platelet aggregation
AE of NSAIDS
Abdominal pain, ulcers, GI bleeding, Decrease renal blood flow, decrease glomerular filtration rate
AE of Aspirin
COX1: Increase risk of bleeding; ANTITHROMBOTIC effect; Used for CV benefits
AE of Celecoxib
COX2: Increase risk of MI and Stroke
AE of Acetaminophen
Liver toxicity (4g/day)
MOA of Opioids in Midbrain
Block release of GABA; Increase activation of noradrenergic descending pain modulation systems; At spinal level, NE and 5HT2 acting through a2 adrenergic and serotonergic receptors, inhibit spinal pain input.
MOA of Opioids in Dorsal Horn
Presynaptic action: Decrease release of neurotransmitter (substance P); Postsynaptic: Hyperpolarization of postsynap. neuron
Describe Opioid AE: Reward
Opioid action leads to sensation of reward (endorphins): Increase substance use disorder
Describe Opioid AE: Drowsiness
Decrease wakefulness and drowsiness (inhibition of excitatory drive from ascending reticular activating system)
Describe Opioid AE: Respiratory depression
Chemosensitive area in brainstem: Block rise of CO2; dependent on fall in O2 (periphery)
Describe Opioid AE:GI
Increase segmental (nonpropulsive) contractions –> constipation; Decrease peristaltic (propulsive) contraction (contraction below, relaxation above)
Describe Opioid AE: N/V
Nausea and emesis: stimulate u-R in CTZ (chemoreceptor trigger zone)
Describe Opioid AE:Urinary retention
Inhibit voiding reflex (opioid naive pt only)
Describe Opioid AE: CV
Bradycardia –> Increase parasympathetic
Hypotension –> Morphine can release histamine from mast cells –> decrease SVR –> Decrease BP
Describe opioid MOA
Opioids stimulate u receptor –> Less GABA, more ACh –> Parasympathetic
Describe Opioid AE: Pruritus (itching)
Morphine can release histamine from mast cells
Describe Opioid AE:Miosis
Results from inhibition of inhibitory GABA interneurons –> Increase para –> miosis
Important sign of opioid intoxication
Describe Opioid AE: Cough suppression
Morphine suppresses cough reflex: Not well understood ?
Clinical uses of Morphine (Full u agonist)
Chronic pain (cancer): PO (1st pass metabolism), intrathecal, epidural
Postoperative Pain: IV, inthrathecal,epidural)
Works in 15-30 min
Morphine AE
Releases histamine from mast cell –> vasodilation, allergic symptoms (pruritus)
Clinical uses of Methadone (Full u agonist)
Chronic Pain
Maintenance drug for opioid-dependent pt (heroin)
Long 1/2 life
Clinical uses of Fentanyl (Full u agonist)
Induction agent of anesthesiology
Chronic pain (transmuscosal, transdermal)
Transmucosal lozenge –> quick onset
Clinical uses of Codeine (Full u agonist)
Mild to moderate pain (ceiling effect)
Dependent on conversion of codeine to morphine by CYP2D6 (liver)
10% population have polymorphism in CYP2D6 –> makes codeine ineffective as analgesic
Clinical uses of Buprenorphine (Partial u agonist)
Post-Op pain
Maintenance drug for opioid-dependent patients
Long 1/2 life
Acts as an agonist in presence of antagonist
MOA of Naloxone (u Antagonists)
Blocks all opioid receptors
Used for opioid overdose
IM, IV, auto-injector
Short 1/2 life
Naloxone auto-injector
Narcan
Evzio –> approved for emergency treatment of OD
MOA of Naltrexone (u Antagonists)
Blocks all opioid receptors
Used for opioid dependence (alcohol dependence)
Administer by PO
CANNOT GIVE FOR AN OVERDOSE!!
MOA of Tramadol
Weakly stimulate u opioid receptors
Weakly inhibit NET and SERT
DONT GIVE WHILE ON AN SSRI
Used for mild to moderate pain (PO)
AE of Tramadol
Risk of causing seizures
CAUTION WITH PT PREEXISTING SEIZURE DISORDERS
DONT GIVE WHILE ON AN SSRI (serotonin syndrome)
Opioid interactions/Tolerance
CYP interactions = Codeine
CNS depressants = BZD, etc.
Tolerance –> Need more of drug to see same effect
Cross tolerance
Degree of tolerance
Clinical uses of Clonidine (a2 agonist)
Used as analgesic and neuropathic pain
Postop and neuropathic pain
MOA: Gi couple (less cAMP, less phos. Ca channel, less exocytosis of SP, less transported to 2nd neuron)
AE of Clonidine
Hypotension
Sedation
Dry mouth (a2 receptors on parasympathetic postgang nerve terminals)
Decrease Ach
Clinical uses of Gabapentin
MOA: Uncertain
Neuropathic pain
Seizures (adjunct therapy)
What drugs prolong the inactivated state of Na and what are the clinical uses?
Carbamazepine, Phenytoin, topiramate
Seizures
Neuropathic pain